The PREVENT Trial
Randomised clinical trial to assess lymphoedema prevention
The results are in.
And they’re conclusive.
PREVENT meets primary endpoint – a detailed look at the 3-year results and expert discussion.
PREVENT, the largest randomized clinical trial to assess lymphoedema prevention met its primary endpoint and reached statistical significance. Watch as our expert panel Dr. Chirag Shah, Dr. Pat Whitworth, and Maureen McBeth dissect the trial results and discuss the implications of this new data to the future of cancer patient care.
Significantly Lower Progression to Chronic Lymphoedema
with early detection using L-Dex and intervention versus using tape measure.
Primary Endpoint Result
L-Dex More Precise and Reliable than Tape Measure
“[L-Dex] is more specific for lymphoedema detection than tape measure.”
“[L-Dex], as compared to tape measure, provides a more precise identification of patients likely to benefit from an early compression intervention.”
— The PREVENT Trial
Ridner SH, et al. A Comparison of Bioimpedance Spectroscopy or Tape Measure Triggered Compression Intervention in Chronic Breast Cancer Lymphedema Prevention. Lymphatic Research and Biology 2022.
Reference in this site to any specific commercial product, process, or service is for the information and convenience of the public, and does not constitute endorsement, recommendation, or favouring by Lymphoedema Education Solutions.
